Active pulmonary tuberculosis in a patient with secukinumab treatment

Numerous investigations have documented active tuberculosis (TB) infection following biologic treatment. One of the most secure biologic medications for infections is secukinumab. Additionally, no cases of active TB while receiving secukinumab therapy were recorded. Secukinumab 150 mg per month has...

Full description

Saved in:
Bibliographic Details
Published inRadiology case reports Vol. 18; no. 1; pp. 239 - 242
Main Authors Ngoc, Cao Thanh, Khoa, Bui Dang, Nguyen, Huynh Khoi, Le, Le Bao, Hiep, Dang Vinh, Duc, Nguyen Minh
Format Journal Article
LanguageEnglish
Published Elsevier Inc 01.01.2023
Elsevier
Subjects
Case Report
Secukinumab
Spondyloarthritis
Tuberculosis
Secukinumab
Spondyloarthritis
Tuberculosis
Online AccessGet full text

Cover

More Information
Summary:Numerous investigations have documented active tuberculosis (TB) infection following biologic treatment. One of the most secure biologic medications for infections is secukinumab. Additionally, no cases of active TB while receiving secukinumab therapy were recorded. Secukinumab 150 mg per month has been administered for a 19-year-old man with spondyloarthritis since May 2020. A diagnosis of pulmonary TB was made when the patient complained of a moderate fever, a productive cough, and weight loss after 2 years. His fever and respiratory symptoms were relieved after 6 weeks of treatment by stopping secukinumab and utilizing 4 antibiotics: isoniazid, rifampicin, pyrazinamide, and ethambutol, while non-steroidal anti-inflammatory drugs reduced his joint and back discomfort. During biological therapy, even with secukinumab, annual screening for latent and active TB is crucial. We require additional study on secukinumab-treated patients with active TB in nations with high TB burdens, including Vietnam.
Bibliography:These authors contributed equally to this article as co-first authors.
ISSN:1930-0433
1930-0433
DOI:10.1016/j.radcr.2022.10.032